Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations

Diego Bagnasco, Matteo Ferrando, Marco Caminati, Alice Bragantini, Francesca Puggioni, Gilda Varricchi, Giovanni Passalacqua, Giorgio Walter Canonica

Research output: Contribution to journalReview article

Abstract

Asthma is a highly prevalent chronic disease of the airways; approximately 10% of patients with asthma will experience a severe form of the disease. New understanding of the pathogenesis of asthma has enabled the development of novel drugs and provided hope for patients with asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) plays a crucial role in the development, maturation, and operation of eosinophils so were the first important therapeutic target of these new drugs. While the results of early clinical trials of these drugs were not promising, results improved once researchers discovered the drugs worked best in patients with high eosinophil levels. Patients treated with both anti-IL-5 and IL-5-Rα experienced significant decreases in exacerbations. Trials have also demonstrated promising safety profiles; adverse events have been few and frequently only observed with placebo or considered unrelated to the study drug. The positive efficacy and safety profiles of these drugs has led to trials with interesting results in other diseases that are also secondary to the action of eosinophils: Churg–Strauss syndrome, hypereosinophilic syndrome, nasal polyposis, chronic obstructive pulmonary disease, atopic dermatitis, and esophagitis. In this review, we explore the main clinical trials of anti-IL-5 and IL-5-Rα, both in asthma and in other pathologies, with particular reference to the interesting safety and efficacy results.

Original languageEnglish
Pages (from-to)559-570
Number of pages12
JournalDrug Safety
Volume40
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Interleukins
Interleukin-5
Safety
Asthma
Eosinophils
Pharmaceutical Preparations
Interleukin-5 Receptors
Clinical Trials
Hypereosinophilic Syndrome
Pulmonary diseases
Esophagitis
Pathology
Atopic Dermatitis
Nose
Chronic Obstructive Pulmonary Disease
Chronic Disease
Placebos
Research Personnel

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Targeting Interleukin-5 or Interleukin-5Rα : Safety Considerations. / Bagnasco, Diego; Ferrando, Matteo; Caminati, Marco; Bragantini, Alice; Puggioni, Francesca; Varricchi, Gilda; Passalacqua, Giovanni; Canonica, Giorgio Walter.

In: Drug Safety, Vol. 40, No. 7, 01.07.2017, p. 559-570.

Research output: Contribution to journalReview article

Bagnasco, D, Ferrando, M, Caminati, M, Bragantini, A, Puggioni, F, Varricchi, G, Passalacqua, G & Canonica, GW 2017, 'Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations', Drug Safety, vol. 40, no. 7, pp. 559-570. https://doi.org/10.1007/s40264-017-0522-5
Bagnasco D, Ferrando M, Caminati M, Bragantini A, Puggioni F, Varricchi G et al. Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations. Drug Safety. 2017 Jul 1;40(7):559-570. https://doi.org/10.1007/s40264-017-0522-5
Bagnasco, Diego ; Ferrando, Matteo ; Caminati, Marco ; Bragantini, Alice ; Puggioni, Francesca ; Varricchi, Gilda ; Passalacqua, Giovanni ; Canonica, Giorgio Walter. / Targeting Interleukin-5 or Interleukin-5Rα : Safety Considerations. In: Drug Safety. 2017 ; Vol. 40, No. 7. pp. 559-570.
@article{eab3d15aa8774fda80aacde21c611adc,
title = "Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations",
abstract = "Asthma is a highly prevalent chronic disease of the airways; approximately 10{\%} of patients with asthma will experience a severe form of the disease. New understanding of the pathogenesis of asthma has enabled the development of novel drugs and provided hope for patients with asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) plays a crucial role in the development, maturation, and operation of eosinophils so were the first important therapeutic target of these new drugs. While the results of early clinical trials of these drugs were not promising, results improved once researchers discovered the drugs worked best in patients with high eosinophil levels. Patients treated with both anti-IL-5 and IL-5-Rα experienced significant decreases in exacerbations. Trials have also demonstrated promising safety profiles; adverse events have been few and frequently only observed with placebo or considered unrelated to the study drug. The positive efficacy and safety profiles of these drugs has led to trials with interesting results in other diseases that are also secondary to the action of eosinophils: Churg–Strauss syndrome, hypereosinophilic syndrome, nasal polyposis, chronic obstructive pulmonary disease, atopic dermatitis, and esophagitis. In this review, we explore the main clinical trials of anti-IL-5 and IL-5-Rα, both in asthma and in other pathologies, with particular reference to the interesting safety and efficacy results.",
author = "Diego Bagnasco and Matteo Ferrando and Marco Caminati and Alice Bragantini and Francesca Puggioni and Gilda Varricchi and Giovanni Passalacqua and Canonica, {Giorgio Walter}",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s40264-017-0522-5",
language = "English",
volume = "40",
pages = "559--570",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "7",

}

TY - JOUR

T1 - Targeting Interleukin-5 or Interleukin-5Rα

T2 - Safety Considerations

AU - Bagnasco, Diego

AU - Ferrando, Matteo

AU - Caminati, Marco

AU - Bragantini, Alice

AU - Puggioni, Francesca

AU - Varricchi, Gilda

AU - Passalacqua, Giovanni

AU - Canonica, Giorgio Walter

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Asthma is a highly prevalent chronic disease of the airways; approximately 10% of patients with asthma will experience a severe form of the disease. New understanding of the pathogenesis of asthma has enabled the development of novel drugs and provided hope for patients with asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) plays a crucial role in the development, maturation, and operation of eosinophils so were the first important therapeutic target of these new drugs. While the results of early clinical trials of these drugs were not promising, results improved once researchers discovered the drugs worked best in patients with high eosinophil levels. Patients treated with both anti-IL-5 and IL-5-Rα experienced significant decreases in exacerbations. Trials have also demonstrated promising safety profiles; adverse events have been few and frequently only observed with placebo or considered unrelated to the study drug. The positive efficacy and safety profiles of these drugs has led to trials with interesting results in other diseases that are also secondary to the action of eosinophils: Churg–Strauss syndrome, hypereosinophilic syndrome, nasal polyposis, chronic obstructive pulmonary disease, atopic dermatitis, and esophagitis. In this review, we explore the main clinical trials of anti-IL-5 and IL-5-Rα, both in asthma and in other pathologies, with particular reference to the interesting safety and efficacy results.

AB - Asthma is a highly prevalent chronic disease of the airways; approximately 10% of patients with asthma will experience a severe form of the disease. New understanding of the pathogenesis of asthma has enabled the development of novel drugs and provided hope for patients with asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) plays a crucial role in the development, maturation, and operation of eosinophils so were the first important therapeutic target of these new drugs. While the results of early clinical trials of these drugs were not promising, results improved once researchers discovered the drugs worked best in patients with high eosinophil levels. Patients treated with both anti-IL-5 and IL-5-Rα experienced significant decreases in exacerbations. Trials have also demonstrated promising safety profiles; adverse events have been few and frequently only observed with placebo or considered unrelated to the study drug. The positive efficacy and safety profiles of these drugs has led to trials with interesting results in other diseases that are also secondary to the action of eosinophils: Churg–Strauss syndrome, hypereosinophilic syndrome, nasal polyposis, chronic obstructive pulmonary disease, atopic dermatitis, and esophagitis. In this review, we explore the main clinical trials of anti-IL-5 and IL-5-Rα, both in asthma and in other pathologies, with particular reference to the interesting safety and efficacy results.

UR - http://www.scopus.com/inward/record.url?scp=85021338013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021338013&partnerID=8YFLogxK

U2 - 10.1007/s40264-017-0522-5

DO - 10.1007/s40264-017-0522-5

M3 - Review article

AN - SCOPUS:85021338013

VL - 40

SP - 559

EP - 570

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 7

ER -